2015\u5e7412\u670804\u65e5<\/p>\n
Veeva Japan\u682a\u5f0f\u4f1a\u793e<\/p>\n
\u3000Veeva Systems Inc.\u3010NYSE:VEEV\u3011(\u672c\u793e:\u30ab\u30ea\u30d5\u30a9\u30eb\u30cb\u30a2\u5dde\u30d7\u30ec\u30b6\u30f3\u30c8\u30f3\u3001\u65e5\u672c\u6cd5\u4eba \u672c\u793e:\u6771\u4eac\u90fd\u6e0b\u8c37\u533a\u3001\u65e5\u672c\u6cd5\u4eba\u4ee3\u8868\u53d6\u7de0\u5f79:\u5ca1\u6751 \u5d07\u3001\u4ee5\u4e0b\u3001Veeva)\u306f\u30012015 \u5e74 11 \u6708 2 \u65e5 \u6cbb\u9a13\u5206\u91ce\u3078\u5b8c\u5168\u306b\u30d1\u30c3\u30b1\u30fc\u30b8\u5316\u3055\u308c\u305f Start-Up \u30bd\u30ea\u30e5\u30fc\u30b7\u30e7\u30f3\u3092\u767a\u8868\u3057\u307e\u3057\u305f\u3002Veeva Vault Study Start-Up \u306b\u3088\u308a\u3001\u30e9\u30a4\u30d5\u30b5\u30a4\u30a8\u30f3\u30b9\u4f01\u696d\u306f\u6cbb\u9a13\u7acb\u3061\u4e0a\u3052\u306b\u95a2\u9023\u3059\u308b\u30b3\u30f3\u30c6\u30f3\u30c4\u3068\u6d3b \u52d5\u3092\u7ba1\u7406\u3059\u308b\u3053\u3068\u304c\u3067\u304d\u307e\u3059\u3002\u3053\u306e\u5305\u62ec\u7684\u30bd\u30ea\u30e5\u30fc\u30b7\u30e7\u30f3\u306f\u3001\u6cbb\u9a13\u95a2\u9023\u30b3\u30f3\u30c6\u30f3\u30c4\u3092\u3072\u3068\u3064\u306e\u30bd\u30fc\u30b9\u306b\u307e\u3068\u3081\u308b eTMF \u5229\u7528\u3067\u3001first patient enrollment \u307e\u3067\u306e\u6642\u9593\u3092\u77ed\u7e2e\u3057\u307e\u3059\u3002 \u307e\u305f\u3001\u624b\u4f5c\u696d\u306e\u30d7\u30ed\u30bb\u30b9\u3092\u81ea\u52d5\u5316\u3057\u3001\u30b9\u30e0\u30fc\u30ba\u306a\u76f8\u4e92\u904b\u7528\u6027\u3092\u5b9f\u73fe\u3057\u307e\u3059\u3002(\u672c\u30ea\u30ea\u30fc\u30b9\u306f\u3001 Veeva \u7c73\u56fd\u672c\u793e\u304c\u767a\u8868\u3057\u305f\u5831\u9053\u8cc7\u6599\u306e\u6284\u8a33\u3067\u3059)<\/p>\n
\u3000\u30e9\u30a4\u30d5\u30b5\u30a4\u30a8\u30f3\u30b9\u4f01\u696d\u306f\u3001\u9ad8\u5ea6\u306a\u30bd\u30ea\u30e5\u30fc\u30b7\u30e7\u30f3\u63a1\u7528\u3067\u9032\u6b69\u3092\u9042\u3052\u3001\u6cbb\u9a13\u30d7\u30ed\u30bb\u30b9\u306e\u69d8\u3005 \u306a\u5206\u91ce\u306b\u304a\u3044\u3066\u30b9\u30d4\u30fc\u30c9\u3084\u52b9\u7387\u3092\u4e0a\u3052\u3066\u3044\u307e\u3059\u30022015 TMF \u30ea\u30d5\u30a1\u30ec\u30f3\u30b9\u30e2\u30c7\u30eb\u30b5\u30fc\u30d9\u30a4\u306b \u3088\u308b\u3068\u3001\u56de\u7b54\u8005\u306e\u5927\u534a(61%)\u306f\u3001eTMF \u3092\u5229\u7528\u3057\u3066\u3044\u308b\u304b\u3001\u305d\u306e\u5229\u7528\u3092\u524d\u5411\u304d\u306b\u691c\u8a0e\u3057\u3066\u3044 \u307e\u3059\u3002\u307e\u305f Veeva 2015 \u30da\u30fc\u30d1\u30fc\u30ec\u30b9 TMF \u30b5\u30fc\u30d9\u30a4\u306b\u3088\u308b\u3068\u3001\u56de\u7b54\u8005\u306e 56%\u304c\u3001\u6cbb\u9a13\u7acb\u3061\u4e0a \u3052\u306e\u30b9\u30d4\u30fc\u30c9\u30a2\u30c3\u30d7\u3092\u3001\u7d44\u7e54\u306b\u304a\u3051\u308b eTMF \u63a1\u7528\u306e\u4e3b\u306a\u4fc3\u9032\u8981\u7d20\u3068\u3057\u3066\u6319\u3052\u3066\u3044\u307e\u3059\u3002<\/p>\n
\u3000Veeva Vault Clinical \u62c5\u5f53\u30d0\u30a4\u30b9\u30d7\u30ec\u30b8\u30c7\u30f3\u30c8\u3001Kathryn King \u306f\u6b21\u306e\u3088\u3046\u306b\u8ff0\u3079\u3066\u3044\u307e \u3059\u3002\u300c\u30e9\u30a4\u30d5\u30b5\u30a4\u30a8\u30f3\u30b9\u696d\u754c\u306f\u3001\u6cbb\u9a13\u306b\u65bc\u3051\u308b\u7acb\u3061\u4e0a\u3052\u6642\u306e\u624b\u4f5c\u696d\u304b\u3064\u975e\u52b9\u7387\u7684\u306a\u30d7\u30ed\u30bb \u30b9\u306b\u9577\u3044\u9593\u60a9\u307e\u3055\u308c\u3066\u304d\u307e\u3057\u305f\u3002\u65e2\u5b58\u306e\u30bd\u30ea\u30e5\u30fc\u30b7\u30e7\u30f3\u306f\u3001\u66f8\u985e\u3042\u308b\u3044\u306f\u6d3b\u52d5\u30de\u30a4\u30eb\u30b9\u30c8 \u30fc\u30f3\u306e\u3044\u305a\u308c\u304b\u3092\u7ba1\u7406\u3067\u304d\u307e\u3057\u305f\u304c\u3001\u4e21\u65b9\u3092\u540c\u6642\u306b\u884c\u3046\u3053\u3068\u306f\u3042\u308a\u307e\u305b\u3093\u3067\u3057\u305f\u3002\u3053\u308c\u306f\u3001 \u7acb\u3061\u4e0a\u3052\u306e\u969b\u306e\u554f\u984c\u306b\u3064\u3044\u3066\u78ba\u8a8d\u3057\u53d6\u308a\u7d44\u3080\u4e0a\u3067\u91cd\u8981\u306a\u8ab2\u984c\u3068\u306a\u308a\u3001\u6cbb\u9a13\u671f\u9593\u3092\u9577\u5f15\u304b\u305b\u3001 \u5e02\u8ca9\u5316\u306b\u304b\u304b\u308b\u671f\u9593\u5168\u4f53\u306b\u5f71\u97ff\u3092\u4e0e\u3048\u3066\u3044\u307e\u3057\u305f\u3002\u300d<\/p>\n
\u3000\u5f93\u6765\u306e\u30bd\u30ea\u30e5\u30fc\u30b7\u30e7\u30f3\u3067\u306f\u3001\u65bd\u8a2d\u306e\u7acb\u3061\u4e0a\u3052\u66f8\u985e\u4f5c\u6210\u3042\u308b\u3044\u306f\u958b\u59cb\u6d3b\u52d5\u30c7\u30fc\u30bf\u306e\u3044\u305a\u308c \u304b\u306b\u7126\u70b9\u3092\u5408\u308f\u305b\u308b\u3053\u3068\u3067\u3001\u3053\u306e\u554f\u984c\u3092\u60aa\u5316\u3055\u305b\u308b\u3070\u304b\u308a\u3067\u3001\u66f8\u985e\u3068\u30c7\u30fc\u30bf\u3092\u3072\u3068\u3064\u306b\u307e \u3068\u3081\u308b\u3053\u3068\u306f\u3067\u304d\u3066\u3044\u307e\u305b\u3093\u3067\u3057\u305f\u3002\u3055\u3089\u306b\u3053\u3046\u3057\u305f\u30b7\u30b9\u30c6\u30e0\u306e\u591a\u304f\u306f\u3001\u6cbb\u9a13\u5c65\u6b74\u306e\u4e00\u90e8 \u3068\u3057\u3066\u5f53\u8a72\u60c5\u5831\u3092\u540c\u69d8\u306b\u5fc5\u8981\u3068\u3059\u308b eTMF \u30a2\u30d7\u30ea\u30b1\u30fc\u30b7\u30e7\u30f3\u304b\u3089\u306f\u5207\u308a\u96e2\u3055\u308c\u3066\u3044\u307e\u3057\u305f\u3002 \u65ad\u7247\u5316\u3055\u308c\u305f\u74b0\u5883\u306f\u3001\u65bd\u8a2d\u306e\u7acb\u3061\u4e0a\u3052\u4e88\u5b9a\u3092\u9577\u5f15\u304b\u305b\u3066\u304a\u308a\u3001Tufts \u5927\u5b66\u533b\u85ac\u54c1\u958b\u767a\u7814\u7a76\u30bb\u30f3\u30bf \u30fc(CSDD)\u306e\u8abf\u3079\u306b\u3088\u308b\u3068\u3001\u9054\u6210\u307e\u3067\u306e\u30d7\u30ed\u30bb\u30b9\u306b\u5e73\u5747 17 \u30ab\u6708\u304b\u304b\u3063\u3066\u3044\u307e\u3057\u305f\u3002<\/p>\n
\u3000Tufts \u5927\u5b66\u533b\u5b66\u90e8 CSDD \u51c6\u6559\u6388 Ken Getz \u6c0f\u306f\u3001\u6b21\u306e\u3088\u3046\u306b\u8ff0\u3079\u3066\u3044\u307e\u3059\u3002\u300c\u30b9\u30dd\u30f3\u30b5\u30fc\u3084 CRO \u306f\u901a\u5e38\u3001\u6cbb\u9a13\u7acb\u3061\u4e0a\u3052\u3084\u958b\u59cb\u6d3b\u52d5\u7ba1\u7406\u306e\u305f\u3081\u306b\u3001\u5358\u7d14\u3067\u3001\u5225\u3005\u306e\u3001\u4e92\u63db\u6027\u306e\u306a\u3044\u72ec\u81ea\u306b \u30ab\u30b9\u30bf\u30de\u30a4\u30ba\u3057\u305f\u30a2\u30d7\u30ed\u30fc\u30c1\u3084\u96fb\u5b50\u81e8\u5e8a\u30bd\u30ea\u30e5\u30fc\u30b7\u30e7\u30f3\u3092\u5229\u7528\u3057\u3066\u304d\u307e\u3057\u305f\u3002\u3053\u306e\u3053\u3068\u304c\u3001 \u6cbb\u9a13\u65bd\u8a2d\u3067\u306e\u696d\u52d9\u3084\u6d3b\u52d5\u306b\u983b\u7e41\u306b\u898b\u3089\u308c\u308b\u3001\u975e\u52b9\u7387\u6027\u3084\u4e00\u8cab\u6027\u306e\u306a\u3055\u306e\u4e00\u56e0\u3068\u306a\u3063\u3066\u3044\u307e \u3057\u305f\u3002\u300d<\/p>\n
\u3000Vault Study Start-Up \u306a\u3089\u3001\u65bd\u8a2d\u7acb\u3061\u4e0a\u3052\u66f8\u985e\u3084\u65bd\u8a2d\u958b\u59cb\u3092\u3001\u3072\u3068\u3064\u306e\u30bd\u30ea\u30e5\u30fc\u30b7\u30e7\u30f3 \u306b\u307e\u3068\u3081\u308b\u3053\u3068\u304c\u3067\u304d\u3001Veeva Vault eTMF \u3068\u306e\u30b9\u30e0\u30fc\u30ba\u306a\u76f8\u4e92\u904b\u7528\u6027\u3092\u3082\u305f\u3089\u3057\u307e\u3059\u3002\u3053 \u306e\u6a5f\u80fd\u306e\u7d44\u307f\u5408\u308f\u305b\u306b\u3088\u308a\u3001\u95a2\u9023\u30b3\u30f3\u30c6\u30f3\u30c4\u3084\u30c7\u30fc\u30bf\u306a\u3069\u3059\u3079\u3066\u306e Start-Up \u6d3b\u52d5\u306e\u771f\u5b9f\u3092 \u8a9e\u308b\u8cc7\u6599\u3092\u3001\u3072\u3068\u3064\u306b\u307e\u3068\u3081\u308b\u3053\u3068\u304c\u3067\u304d\u307e\u3059\u3002\u65bd\u8a2d\u3001\u30b9\u30dd\u30f3\u30b5\u30fc\u3001CRO \u304c\u3001\u540c\u3058\u81e8\u5e8a\u60c5\u5831 \u306b\u30a2\u30af\u30bb\u30b9\u3059\u308b\u3053\u3068\u304c\u3067\u304d\u3001\u9023\u643a\u3092\u7c21\u7d20\u5316\u3057\u3001\u52b9\u7387\u3092\u9ad8\u3081\u308b\u3053\u3068\u304c\u3067\u304d\u307e\u3059\u3002Vault Study Start-Up \u306f\u307e\u305f\u3001\u5b8c\u5168\u3067\u78ba\u5b9f\u306a\u96fb\u5b50\u76e3\u67fb\u8a3c\u8de1\u306a\u3069\u3001\u7acb\u3061\u4e0a\u3052\u30d7\u30ed\u30bb\u30b9\u306e\u7ba1\u7406\u3092\u6539\u5584\u3059\u308b\u9ad8 \u5ea6\u306a\u6a5f\u80fd\u3082\u6709\u3057\u3066\u3044\u307e\u3059\u3002<\/p>\n
Veeva Systems \u793e\u306b\u3064\u3044\u3066<\/strong> Forward-looking Statements<\/strong> 2015\u5e7412\u670804\u65e5 Veeva Japan\u682a\u5f0f\u4f1a\u793e \u3000Veeva Systems Inc.\u3010NYSE:VEEV\u3011(\u672c\u793e:\u30ab\u30ea\u30d5\u30a9\u30eb\u30cb\u30a2\u5dde\u30d7\u30ec\u30b6\u30f3\u30c8\u30f3\u3001\u65e5\u672c\u6cd5\u4eba \u672c\u793e:\u6771\u4eac\u90fd\u6e0b\u8c37\u533a\u3001\u65e5\u672c\u6cd5\u4eba\u4ee3\u8868\u53d6\u7de0\u5f79:\u5ca1\u6751 \u5d07\u3001\u4ee5\u4e0b\u3001…<\/p>\n","protected":false},"author":129,"featured_media":37545,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[322],"tags":[],"class_list":["post-37673","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-press-release","blog-product-veeva-vault"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/posts\/37673"}],"collection":[{"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/comments?post=37673"}],"version-history":[{"count":2,"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/posts\/37673\/revisions"}],"predecessor-version":[{"id":37825,"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/posts\/37673\/revisions\/37825"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/"}],"wp:attachment":[{"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/media?parent=37673"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/categories?post=37673"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/tags?post=37673"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nVeeva Systems \u793e\u306f\u30b0\u30ed\u30fc\u30d0\u30eb\u306a\u30e9\u30a4\u30d5\u30b5\u30a4\u30a8\u30f3\u30b9\u4f01\u696d\u5411\u3051\u306b\u30af\u30e9\u30a6\u30c9\u30d9\u30fc\u30b9\u306e\u30bd\u30ea\u30e5 \u30fc\u30b7 \u30e7\u30f3\u3092\u63d0\u4f9b\u3059\u308b\u30ea\u30fc\u30c7\u30a3\u30f3\u30b0\u30ab\u30f3\u30d1\u30cb\u30fc\u3067\u3059\u3002\u4e16\u754c\u6700\u5927\u898f\u6a21\u306e\u88fd\u85ac\u4f1a\u793e\u304b\u3089\u30d0\u30a4 \u30aa\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u5206\u91ce\u306e\u65b0\u8208\u4f01\u696d\u307e\u3067 300 \u793e\u3092\u8d85\u3048\u308b\u9867\u5ba2\u3092\u64c1\u3057\u3001\u6280\u8853\u9769\u65b0\u3078\u306e\u53d6\u308a\u7d44\u307f \u3084\u5353\u8d8a\u3057\u305f\u88fd\u54c1\u529b\u306b\u3088\u3063\u3066\u3001\u304a\u5ba2\u69d8\u306e\u6210\u529f\u3092\u30b5\u30dd\u30fc\u30c8\u3057\u3066\u3044\u307e\u3059\u3002Veeva \u306f\u3001\u30b5\u30f3\u30d5\u30e9 \u30f3\u30b7\u30b9\u30b3\u306e\u30d9\u30a4\u30a8\u30ea\u30a2\u306b\u672c\u793e\u3092\u7f6e\u304d\u3001\u30e8\u30fc\u30ed\u30c3\u30d1\u3001\u30a2\u30b8\u30a2\u3001\u30e9\u30c6\u30f3\u30a2\u30e1\u30ea\u30ab\u306b\u62e0\u70b9\u3092\u5c55 \u958b\u3057\u3066\u3044\u307e\u3059\u3002\u8a73\u3057\u304f\u306f\u3001\u516c\u5f0f\u30b5\u30a4\u30c8 <\/a>\u3092\u3054\u89a7\u304f\u3060\u3055\u3044\u3002<\/p>\n
\nThis release contains forward-looking statements, including the market demand for and acceptance of Veeva\u2019s products and services, the results from use of Veeva\u2019s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva\u2019s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva\u2019s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva\u2019s financial results are included under the captions, \u201cRisk Factors\u201d and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations\u201d in the company\u2019s filing on Form 10-Q for the period ended July 31, 2015. This is available on the company\u2019s website at http:\/\/www.veeva.com under the Investors section and on the SEC\u2019s website at www.sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.<\/p>\n","protected":false},"excerpt":{"rendered":"